- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | BTIG reiterates Neutral rating on Globus Medical stock after strong Q3 | ||
| Di | FMR LLC and FIL Limited disclose 4.51% stake in Permanent TSB | ||
| Di | Surf Air Mobility allocates $26 million to fund AI-enabled SurfOS | ||
| Di | TNL Mediagene projects $49.1 million revenue for 2025 | ||
| Di | Soulpower Acquisition submits confidential S-4 for SOUL WORLD BANK merger | ||
| Di | Aflac stock price target raised to $119 by Raymond James on strong outlook | ||
| Di | Airbus to lead Spanish Air Force's combat training system overhaul | ||
| Di | Bank of America discloses 2.39% stake in Avadel Pharmaceuticals | ||
| Di | T1 Energy completes transactions to maintain FEOC compliance for 2026 | ||
| Di | Cango secures $10.5 million investment from major shareholder EWCL | ||
| Di | Hyperscale Data's bitcoin holdings exceed market capitalization | ||
| Di | Euro Tech reports 18.9% revenue drop in first half of 2025 | ||
| Di | VCI Global reaffirms commitment to Oobit ecosystem development | ||
| Di | T1 Energy completes $160 million sale of production tax credits | ||
| Di | CTT Pharmaceutical files S-1 registration statement with SEC | ||
| Di | Ecobank Nigeria completes tender offer for senior note participation notes | ||
| Di | Saba requisitions meeting to replace Edinburgh Worldwide directors | ||
| Di | Activist investor targets Target stock amid operational challenges | ||
| Di | Jefferies lowers Ultragenyx Pharma stock price target to $63 on trial miss | ||
| Di | Jefferies reiterates Buy rating on Vipshop stock with $22.60 target | ||
| Di | William Blair reiterates Outperform rating on Acuity Brands stock | ||
| Di | Stifel reiterates Hold rating on Lululemon stock amid proxy contest | ||
| Di | William Blair reiterates Outperform rating on AAON stock amid expanded credit facility | ||
| Di | Wells Fargo lowers Ultragenyx Pharma stock price target to $45 from $65 | ||
| Di | Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .